Nocdurna (Desmopressin)

Desmopressin mimics the natural hormone vasopressin. It binds to V2 receptors in the kidney, triggering a cascade that inserts aquaporin‑2 channels into the collecting‑duct cells, allowing more water to be reabsorbed. It also activates V1 receptors on endothelial cells, promoting release of clotting factors that aid hemostasis.

The appropriate dose of Nocdurna is determined by the prescribing healthcare professional based on the individual’s condition, age, renal function and response. Dosing regimens vary for diabetes insipidus, nocturnal enuresis and bleeding disorders, and should follow the prescriber’s instructions.

Safety data for desmopressin during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To order Nocdurna, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nocdurna (desmopressin) is a synthetic vasopressin analog with greater selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic drugs, it provides reliable control of urine output with a lower risk of hypertension but still requires monitoring for hyponatremia.

Nocdurna should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or other humid environments.

Nocdurna is administered as a sublingual tablet. The tablet should be placed under the tongue and allowed to dissolve completely without chewing or swallowing. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption.

The most serious risks include severe hyponatremia, which can lead to seizures or coma, and rare thromboembolic events such as deep‑vein thrombosis. Prompt monitoring of serum sodium and vigilance for signs of clot formation are essential, especially in patients receiving high‑dose or prolonged therapy.

Nocdurna is contraindicated in patients with uncontrolled hyponatremia, severe renal impairment, or known hypersensitivity to desmopressin. Caution is also advised for individuals with uncontrolled hypertension, active thromboembolic disease, or those taking other potent antidiuretic agents.